CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ZYUS Life Sciences Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ZYUS Life Sciences Corp
204 - 407 Downey Road
Phone: (306) 242-2357p:306 242-2357 SASKATOON, SK  S7N 4L8  Canada Ticker: ZYUSZYUS
Business Summary
ZYUS Life Sciences Corporation is a Canada-based life sciences company. It develops and commercializes novel cannabinoid-based pharmaceutical drug candidates for pain management. Its lead research program is focused on developing a highly purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its pre-and non-clinical studies provide the foundation for clinical investigations of its drug candidates in humans. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman RichardHoyt 6/9/2023 6/9/2023
President, Chief Executive Officer, Company Secretary, Director BrentZettl 6/9/2023 6/9/2023
Chief Financial Officer JohnHyshka 6/9/2023 6/9/2023
7 additional Officers and Directors records available in full report.

Business Names
Business Name
PCO
Phoenix International Energy Inc.
ZYUS

General Information
Number of Employees: 2 (As of 12/31/2005)
Outstanding Shares: 74,357,741 (As of 9/30/2024)
Shareholders: 61
Stock Exchange: CVE
Fax Number: (416) 368-4440


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, January 28, 2025